News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase III
Relypsa, Inc. (RLYP) Announces Data Published In The New England Journal of Medicine For Pivotal Phase 3 Program Of Patiromer FOS For The Treatment Of Hyperkalemia 11/21/2014
ZS Pharma (ZSPH) Announces Publication Of Results From Phase 3 Study Of ZS-9 In Patients With Hyperkalemia In The New England Journal of Medicine 11/21/2014
Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For Veltuzumab For The Treatment Of Pemphigus 11/21/2014
Immunomedics, Inc. (IMMU) Presents Clinical Data On Novel Antibody-Drug Conjugates For Solid Cancer Therapy 11/21/2014
Top 10 Countries For Diabetes Clinical Research 11/20/2014
Regeneron (REGN), ReGen Therapeutics Plc (RGT.L) Eczema Drug Dupilumab Gets Sanofi (SAN.PA) Breakthrough Therapy Designation 11/20/2014
Sanofi (SAN.PA) And Regeneron (REGN)'s Alirocumab Ph3 Trials Met Primary Efficacy Endpoint 11/20/2014
Charleston Laboratories, Inc. And Daiichi Sankyo, Inc. (4568.t) Initiate Two Phase 3 Clinical Trials On Charleston's Lead Product, CL-108 11/20/2014
TrovaGene, Inc. Releases Clinical Study Results For The Detection And Monitoring Of KRAS Mutations In Circulating Tumor DNA Of Colorectal Cancer Patients 11/20/2014
Auxilium Pharmaceuticals (AUXL) Presents XIAFLEX For Peyronie's Disease Data At SMSNA Scientific Meeting 11/20/2014
Titan Pharmaceuticals (TTP) Announces Completion Of Enrollment In Phase 3 Study Of Probuphine For Opioid Dependence 11/20/2014
Merrimack Pharmaceuticals Inc. (MACK) Receives FDA Fast Track Designation For MM-398 In Post-Gemcitabine Metastatic Pancreatic Cancer 11/19/2014
FDA Puts Partial Hold On CytRx Corporation (CYTR)'s Aldoxorubicin Clinical Trials 11/19/2014
SOTIO Initiates US Part Of VIABLE, A Global Phase III Clinical Trial For Prostate Cancer Immunotherapy Treatment With DCVAC/PCa 11/19/2014
Amgen (AMGN) Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 11/19/2014
Genzyme Corporation (GENZ) And Isis Pharmaceuticals, Inc. (ISIS) Present KYNAMRO® Clinical Data At American Heart Association 11/19/2014
ZS Pharma (ZSPH) Presents Positive Results From HARMONIZE (ZS004), A Second Phase 3 Clinical Trial Of ZS-9 In Patients With Hyperkalemia, At The American Heart Association Scientific Meeting And Announces Simultaneous Publication Of Results In JAMA 11/17/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Publication Of Phase 3 Study Of Once Daily Envarsus® XR Demonstrating Non-Inferiority Vs. Twice-Daily Tacrolimus In De Novo Kidney Transplant Patients 11/17/2014
Novartis Pharmaceutical Corporation (NVS) AIN457 (secukinumab) Showed Significant Symptom Improvement In Two Pivotal Phase 3 ankylosing spondylitis Studies 11/17/2014
TissueGene, Inc. Receives Recommendations From FDA On Pathway To Phase 3 Trial Of TG-C For Treatment Of Osteoarthritis Of The Knee 11/17/2014
Keryx Biopharmaceuticals (KERX) Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study 11/17/2014
Amicus Therapeutics, Inc. (FOLD) Announces Positive Phase 3 Data On Cardiac And Composite Endpoints From Fabry Monotherapy Study 012 At American Society of Nephrology 11/17/2014
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company (BMY) And Pfizer (PFE) Announce Statistically Significant Results From The First Part Of The Phase 3 ANNEXA(TM)-A Studies Of Investigational Andexanet Alfa With Eliquis (Apixaban) 11/17/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Late-Breaking Presentation Of Phase 3 VALOR Trial At American Society of Hematology Annual Meeting 11/17/2014
Bristol-Myers Squibb Company (BMY) Release: Study Comparing Opdivo (Nivolumab) To Chemotherapy In Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor To Demonstrate A Survival Benefit In A Phase 3 Trial 11/17/2014
Ipsen Biopharmaceuticals, Inc. Presents Dysport® (abobotulinumtoxinA) Data At American Academy Of Physical Medicine And Rehabilitation Annual Assembly 11/17/2014
Bristol-Myers Squibb Company (BMY) Release: Analyses From Phase 3b Study Provide Additional Data In Earlier Use Of Orencia (Abatacept) Plus Methotrexate (MTX) In Citrullinated Protein (CCP)-Positive Adult Patients With Early Rheumatoid Arthritis (RA) 11/17/2014
Nine New Analyses Show Novartis Pharmaceuticals Corporation (NVS)' LCZ696 Could Change Course Of Heart Failure For Patients 11/17/2014
Eli Lilly (LLY) Release: New Retrospective Data Showed Empagliflozin Reduced A1C, Body Weight And Markers Of Abdominal Fat In Adults With Type 2 Diabetes 11/17/2014
Iroko Pharmaceuticals Release: New Long-Term Safety And Quality Of Life Data Reported For ZORVOLEX® In Osteoarthritis Patients 11/17/2014
AstraZeneca PLC (AZN) Presents Data From Phase 3 Studies Of Lesinurad In Combination With Allopurinol In Gout Patients At American College of Rheumatology 2014 Annual Meeting 11/17/2014
NovoCure Ltd. Announces The EF-14 Phase 3 Clinical Trial Of Tumor Treating Fields In Patients With Newly Diagnosed Glioblastoma Has Been Terminated At The Interim Analysis Due To Early Success 11/17/2014
Provectus Biopharmaceuticals Inc.’ Protocol For Phase 3 Study Of PV-10 As Treatment For Melanoma Now Available Online 11/13/2014
Animal Study Confirms Results Of ChromaDex, Inc. Human Clinical Study On Weight Loss With Pterostilbene 11/12/2014
TiGenix Completes Patient Recruitment For The European Phase 3 Trial Of Cx601 Ahead Of Schedule 11/12/2014
Amgen (AMGN) And AstraZeneca PLC (AZN) Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 11/12/2014
Amgen (AMGN) And AstraZeneca PLC (AZN)'s Psoriasis Drug Tops Johnson & Johnson (JNJ)'s Stelara In Phase 3 Study 11/12/2014
SSF's Threshold Pharmaceuticals, Inc. (THLD) Snags Fast Track Status For Experimental Cancer Drug TH-302 11/11/2014
Threshold Pharmaceuticals, Inc. (THLD) Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previously Untreated Patients With Metastatic Or Locally Advanced Unresectable Soft Tissue Sarcoma 11/11/2014
Highland Therapeutics Announces Positive Top-Line Data From Phase 3 Trial 11/11/2014
Synageva BioPharma (GEVA) Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency At The American Association for Study of Liver Diseases Meeting 11/11/2014
BioCardia Announces FDA Acceptance Of Phase 3 Clinical Trial Protocol Studying Bone Marrow-Derived Cell Therapy For Heart Failure Patients 11/11/2014
Threshold Pharmaceuticals, Inc. (THLD) Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previously Untreated Patients With Metastatic Or Locally Advanced Unresectable Soft Tissue Sarcoma 11/11/2014
BioCardia Announces FDA Acceptance Of Phase 3 Clinical Trial Protocol Studying Bone Marrow-Derived Cell Therapy For Heart Failure Patients 11/11/2014
FDA Grants QIDP Fast-Track Designation To RedHill Biopharma Ltd. (RDHL)'s Phase 3 H. Pylori Drug RHB-105 11/10/2014
Bristol-Myers Squibb Company (BMY) Release: Phase 3 UNITY Trials Demonstrate High Cure Rates For Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination In Genotype 1 Hepatitis C Patients, Including Those With Cirrhosis 11/10/2014
Bristol-Myers Squibb Company (BMY) Release: ALLY Trial Demonstrates High Cure Rates For Investigational Daclatasvir And Sofosbuvir Combination Among Genotype 3 Hepatitis C Patients 11/10/2014
Dynavax Technologies Corporation (DVAX) Announces Independent DSMB Recommendation To Continue Phase 3 Study Of HEPLISAV-B™ 11/10/2014
Cardiome Pharma Corp. (COM.TO) Touts Positive Data From Phase 3 BRINAVESS® Trial 11/7/2014
Amgen (AMGN) Highlights New Data In The Treatment Of Blood Cancers At American Society of Hematology 2014 11/7/2014
Provectus Biopharmaceuticals Inc. Submits PV-10 Phase 3 Melanoma Protocol To FDA 11/7/2014
Spark Therapeutics Snags FDA Breakthrough Therapy Designation For Lead Product 11/6/2014
Genmab A/S (GEN.CO) Announces Additional Data From Phase 3 Study Of Ofatumumab As Maintenance Therapy For Relapsed CLL 11/6/2014
ZS Pharma (ZSPH) Announces Late Breaking Presentation Of Phase 3 HARMONIZE (ZS004) Trial Results In Patients With Hyperkalemia At American Heart Association Annual Meeting 11/6/2014
Exelixis, Inc. (EXEL) Completes Enrollment Of The METEOR Phase 3 Pivotal Trial Of Cabozantinib In Metastatic Renal Cell Carcinoma 11/6/2014
Auspex Pharmaceuticals Receives FDA Orphan Drug Designation Of SD-809 For Treatment Of Huntington's Disease 11/6/2014
Nine Out Of 10 Lost Weight With Novo Nordisk A/S (NVO)'s Obesity Drug Liraglutide 11/5/2014
Amgen (AMGN) Drug Fails To Increase Overall Survival In Ovarian Cancer Patients 11/5/2014
Celsion Corporation (CLSN) Receives VHP Approval To Initiate OPTIMA Study In Europe 11/5/2014
AstraZeneca PLC (AZN) And Pharmacyclics, Inc. (PCYC) Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers 11/5/2014
Ironwood Pharmaceuticals (IRWD) Initiates Phase 3 Trial Of 72 mcg Linaclotide In Adult Patients With Chronic Idiopathic Constipation 11/5/2014
The Medicines Company (MDCO) Announces First Patient Enrollment In Phase 3 Studies Of CARBAVANCE™ In Development For The Treatment Of Serious Bacterial Infections Due To Gram-Negative Bacteria 11/5/2014
Sanofi Pasteur (SASY.PA)'s Investigational Dengue Vaccine Hits Main Goal Showing Efficacy In Phase 3 Trial 11/4/2014
Novo Nordisk A/S (NVO) Release: New Phase 3a Data Demonstrate That 9 Out Of 10 Adults With Obesity Lost Weight With Liraglutide 3 Mg And Clinical Trial Completers Lost An Average Of 9.2% 11/4/2014
XOMA (US) LLC (XOMA) Initiates Pivotal Phase 3 Gevokizumab Study In Patients With Pyoderma Gangrenosum 11/4/2014
Nymox Pharmaceutical (NYMX) Tanks As Lead Drug Fails To Meet Primary Endpoints In Two Large Studies 11/4/2014
Threshold Pharmaceuticals, Inc. (THLD)' Partner Merck KGaA (MKGAF.PK), Darmstadt, Germany, Completes Target Enrollment In The TH-302 Phase 3 MAESTRO Study In Patients With Locally Advanced Or Metastatic Pancreatic Adenocarcinoma 11/4/2014
Nymox Pharmaceutical (NYMX) NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 And NX02-0018 Fail To Meet Primary Efficacy Endpoints 11/3/2014
Nuvo Research Inc. (NRI.TO) Plans Phase 3 Study Of Pennsaid® 2% To Support International Regulatory Approvals 11/3/2014
CEL-SCI (CVM) Enrolls 22 Patients During October In Its Phase 3 Immunotherapy Head And Neck Cancer Trial 11/3/2014
FDA Grants Orphan Drug Designation To Astellas Pharma Inc. (ALPMY) For Isavuconazole For The Treatment Of Invasive Candidiasis 11/3/2014
Antares Pharma, Inc. (ATRS) Announces Last Patient Enrolled In Phase 3 QuickShot® Study Evaluating Testosterone-Deficient Adult Males 11/3/2014
ZS Pharma (ZSPH) Announces Multiple Presentations From ZS003, A Phase 3 Trial Of ZS-9, At The American Society of Nephrology Annual Meeting 10/31/2014
AVANIR Pharmaceuticals (AVNR) Announces Publication Of Pivotal Phase 3 Results From AVP-825 Acute Migraine Study In The Journal "Headache" 10/31/2014
Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) To Be PBS Listed For Metastatic Pancreatic Cancer 10/31/2014
CSL Behring Release: Evidence Presented At The 16th Biennial Meeting Of The European Society For Immunodeficiencies (ESID) Supports Individualized Dosing With Hizentra® 10/31/2014
Medivation, Inc. (MDVN) And Astellas Pharma US Announce Phase 3 Study Of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy 10/31/2014
Arena Pharmaceuticals, Inc. (ARNA) Skimps On Data Disclosure From Weight-Loss Combo Study: Analyst 10/30/2014
Promising Data Presented At The Chicago Multidisciplinary Symposium On Thoracic Oncology From An Investigator-Sponsored Trial Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab In Combination With Pemetrexed And Carboplatin In Front-Line Non-Small Cell Lung Cancer 10/30/2014
Versartis, Inc. (VSAR) Schedules Conference Call To Discuss Plans For Phase 3 Trial For VRS-317 In Pediatric Growth Hormone Deficiency Patients 10/30/2014
Helsinn Group Release: New Data On Fatigue From ROMANA 1, A Pivotal Phase III Study Of Anamorelin In Advanced NSCLC Patients With Cachexia Presented At 2014 Chicago Multidisciplinary Symposium In Thoracic Oncology 10/30/2014
Auspex Pharmaceuticals Initiates Second Pivotal Clinical Trial For SD-809 In Tardive Dyskinesia 10/30/2014
Neurocrine Biosciences, Inc. (NBIX) Receives Breakthrough Therapy Designation For NBI-98854 In Tardive Dyskinesia 10/30/2014
Novartis AG (NVS) Expects New Heart Failure Drug As "Multi-Blockbuster" 10/29/2014
The Medicines Company (MDCO) Announces Presentation Of Investigational Hemostatic Agent RAPLIXA™ (Fibrin Sealant) Phase 3 FINISH-3 Trial Results At The 2014 Clinical Conference Of American College of Surgeons 10/29/2014
Adamas Pharmaceuticals (ADMS) Expands Its Phase 3 Program With ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Patients With Parkinson's Disease 10/29/2014
Lipid Therapeutics' European Partner Dr. Falk Pharma Gmbh Enrolls First Patients Into Pivotal Phase 3 Trial With LT-02, A Novel Therapy For Ulcerative Colitis (UC) 10/29/2014
New Clinical Trial Data: The Scripps Research Institute MS Drug Candidate Also Shows Promise For Ulcerative Colitis 10/28/2014
Catalyst Pharmaceutical Partners, Inc. (CPRX) To Present Firdapse Phase 3 Trial Results At The 61st Annual Meeting Of The American Association Of Neuromuscular And Electrodiagnostic Medicine 10/27/2014
Celator Pharmaceuticals, Inc. Announces Phase 3 Clinical Study Of CPX-351 Achieved Target Enrollment In High Risk (Secondary) Acute Myeloid Leukemia 10/27/2014
Burzynski Research Institute Announces FDA Permission To Launch A New Clinical Trial In Diffuse Intrinsic Brainstem Glioma 10/27/2014
CorMedix (CRMD) Receives Approval From FDA To Initiate A Clinical Trial For Neutrolin In The U.S. 10/27/2014
Alchemia (ACL.AX) Announces Phase 3 Trial Results For HA-Irinotecan In Metastatic Colorectal Cancer 10/27/2014
Metanome, Inc. Selected As Metagenics Inc. Provider For Seres Health Clinical Trial 10/27/2014
Alchemia (ACL.AX) Shares Plummet On Failed Colorectal Cancer Trial 10/27/2014
Roche (RHHBY) Release: CHMP Recommends Label Update For Esbriet In Idiopathic Pulmonary Fibrosis, Strengthening Mortality Benefit And Reinforcing Safety Profile 10/24/2014
Alcobra (ADHD) Announces Presentation Of New Data From Phase 3 Adult ADHD Study At AACAP Annual Meeting 10/23/2014
Novartis AG (NVS)'s AIN457 Meets Primary Endpoint In Two Late Stage Studies 10/23/2014
MorphoSys AG To Receive Milestone Payment For Guselkumab Phase 3 Program 10/23/2014
Upsher-Smith Laboratories Presents New Data On The Administration Of Qudexy™ XR (Topiramate) Extended-Release Capsules Through Enteral Feeding Tubes 10/23/2014
Derma Sciences, Inc. (DSCI) Presented Clinical Evidence And Data On Its Tissue Regeneration Products for Diabetic Foot Ulcers At Fall 2014 Symposium On Advanced Wound Care 10/23/2014
St. Jude Children's Research Hospital Release: Experimental Breast Cancer Drug Holds Promise In Combination Therapy For Ewing Sarcoma 10/23/2014
AcelRx Pharmaceuticals (ACRX)'s Zalviso Met Primary Endpoint In Phase 3 Study 10/22/2014
Repros Therapeutics Inc. (RPRX) Release: Results From Long-Term Study Of Androxal® Exhibit Positive Safety Profile 10/22/2014
Immune Pharmaceuticals, Inc. Release: New Clinical Data Supports Development Of Bertilimumab In Both Ulcerative Colitis And Crohn's Disease 10/22/2014
Despite Conflicting Data, Cytokinetics, Inc. (CYTK) Plans To Take ALS Drug Into Late Stage Study 10/21/2014
Neurocrine Biosciences, Inc. (NBIX) Announces Initiation Of Phase 3 Study For VMAT2 Inhibitor NBI-98854 10/21/2014
Boehringer Ingelheim Corporation Initiates Global Phase 3 Study Investigating Nintedanib In Patients With Colorectal Cancer 10/21/2014
Salix Pharmaceuticals, Ltd. (SLXP)’s TARGET 3 Study Examines The Safety And Efficacy Of Repeat Treatment With Rifaximin 550 mg For Irritable Bowel Syndrome With Diarrhea 10/21/2014
Regeneron (REGN), Sanofi (SAN.PA) Begin Pivotal Phase 3 Study For Eczema Drug Dupilumab 10/20/2014
Amicus Therapeutics, Inc. (FOLD) Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011 10/20/2014
Taiho Oncology Receives D&A Pharma Fast Track Designation For TAS-102 As A Potential Treatment For Refractory Metastatic Colorectal Cancer 10/20/2014
ChemoCentryx, Inc. (CCXI) Releases Phase 3 SHIELD 4 Clinical Results In Patients With Crohn's Disease 10/20/2014
RegeneRx Biopharmaceuticals, Inc. (RGRX) Allowed To Proceed With Phase 3 Using RGN-259 Eye Drops For The Treatment Of Neurotrophic Keratopathy 10/20/2014
Results From Two Phase 3 Studies Added To U.S. Label Of Genzyme’s Aubagio 10/20/2014
Basilea Pharmaceutica (BSLN.SW) Reports Protocol Amendment Resulting In Earlier Completion Of Isavuconazole Phase 3 Invasive Candidiasis Study 10/16/2014
Nanobiotix Receives First Approval To Start Phase 2/3 Registration Trial In Soft Tissue Sarcoma In Europe 10/16/2014
PROMETHERA Biosciences S.A./N.V. Receives Approval In Belgium To Enroll Patients In The Imminent HEP002 Phase 2b/3 Clinical Trial 10/15/2014
Peregrine Pharmaceuticals, Inc. (PPHM) Release: Data To Be Published In The Journal Of Immunology Research Support Phosphatidylserine (PS) As A Potential Target In Ebola Infection 10/15/2014
Novartis AG (NVS)'s Secukinumab Has Consistent Activity In Psoriasis 10/14/2014
Noven Pharmaceuticals Inc. Announces Publication Of Exploratory Analyses From Pooled Phase 3 Results Of The Effects Of Brisdelle® (Paroxetine) Capsules On Weight And Sexual Function During Treatment Of Vasomotor Symptoms Associated With Menopause 10/14/2014
Pacira Pharmaceuticals, Inc. (PCRX) Announces Additional Data Supporting Safety Of EXPAREL® In Peripheral Nerve Block 10/14/2014
Smith & Nephew plc (SNN)’s “Spray-On-Skin” For Leg Ulcers Flops In Trial 10/13/2014
Ipsen (IPN.PA) Announces Positive Results From Phase III Clinical Study Of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered By Subcutaneous Route To Prostate Cancer Patients 10/13/2014
Cardio3 BioSciences Receives Authorization To Enroll Patients In Switzerland In Its Phase 3 Clinical Trial Chart-1 10/13/2014
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce Presentation Of Lorcaserin Hcl Data At The American College Of Clinical Pharmacy Annual Meeting 10/13/2014
AbbVie (ABBV) Announces Late-Breaking Results From Phase 3 Trial Of HUMIRA® (Adalimumab) In Hidradenitis Suppurativa (HS) Patients At The European Academy Of Dermatology And Venereology Congress 10/13/2014
Isis Pharmaceuticals, Inc. (ISIS) Launches Key Trial Of Drug For Rare Spine Disorder 10/10/2014
Bioniche Life Sciences Inc. (BNC) To Publish Comprehensive Phase 3 Clinical Trial Results In The Journal Of Urology 10/10/2014
Alchemia Announces Database Lock Of Its HA-Irinotecan Pivotal Phase 3 Trial In Metastatic Colorectal Cancer 10/10/2014
AcelRx Pharmaceuticals (ACRX) Announces Multiple Sublingual Sufentanil Data Presentations At The American Society Of Anesthesiologists Meeting 10/10/2014
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce Publication Of Pooled Phase 3 Clinical Trial Analysis Of BELVIQ® (Lorcaserin Hcl) CIV In Postgraduate Medicine 10/10/2014
Cyclacel Pharmaceuticals, Inc. (CYCC) Announces Data Safety Monitoring Board Recommendation To Continue The Seamless Phase 3 Trial Of Sapacitabine In AML 10/9/2014
Amgen (AMGN)'s ABP 501 Met Primary Endpoint In Phase 3 Psoriasis Study 10/9/2014
Otonomy, Inc. (OTIC) Enrolls First Meniere's Disease Patients In OTO-104 Multiple-Dose Safety Study 10/9/2014
Vertex Pharmaceuticals (MA) (VRTX) Reviews Recent Progress And Announces Upcoming Milestones In The Development Of Multiple Combinations Of Medicines That Target The Underlying Cause Of Cystic Fibrosis 10/9/2014
InSightec To Share Key Insights And Progress At The 4th Focused Ultrasound International Symposium 10/9/2014
Boston Therapeutics, Inc. Reports Topline U.S.-Based Phase 2b Study Results Of BTI-320 In Patients With Type 2 Diabetes 10/9/2014
Nabriva Therapeutics Announces Qualified Infectious Disease Product And Fast Track Status Granted By The US FDA For Lefamulin 10/8/2014
Catalyst Pharmaceutical Partners, Inc. (CPRX) To Present Top-Line Safety And Efficacy Results From Phase 3 Firdapse Trial At 139th Annual Meeting Of The American Neurological Association 10/8/2014
Astellas Pharma Inc. (ALPMY) Presents New Findings For Isavuconazole In Mucormycosis At IDWeek 10/8/2014
Synageva BioPharma (GEVA) Release: Sebelipase Alfa Phase 3 Data In Children And Adults With LAL Deficiency Selected For Oral Presentation During The Late-Breaking Session At The Liver Meeting® 10/8/2014
Ocular Therapeutix, Inc. (OCUL) Completes Enrollment In Phase 3 Sustained Release Dexamethasone Trials For Post-Operative Inflammation And Pain 10/8/2014
Acacia Pharma Touts Positive Phase 3 Data For APD421 10/7/2014
SSF-Based Sunesis Pharmaceuticals, Inc. (SNSS)'s Shares Crater After Failed Phase 3 Cancer Drug Study 10/7/2014
Pinnacle Biologics, A Subsidiary Of Concordia Healthcare Corp (CXR.TO), Announces European Site Initiation Of Phase 3 Bile Duct Cancer Trial Using Photodynamic Therapy With PHOTOFRIN® 10/7/2014
Immunotech Laboratories Updates Progress On Negotiations For Phase 3 Testing On Its Treatments For HIV/AIDS And Hepatitis C Viruses In Macedonia And Serbia 10/7/2014
TetraPhase Pharmaceuticals Announces Initiation Of Pivotal Portion Of IGNITE 2 Phase 3 Trial Of Eravacycline In CUTI 10/7/2014
Alcobra (ADHD)'s ADHD Drug Metadoxine Meets Goals In Late-Stage Study 10/6/2014
NeoStem, Inc. Announces USAN Approval Of Generic Name 'Eltrapuldencel-T' For Investigational Patient-Specific Targeted Cancer Immunotherapy 10/6/2014
AnGes MG Inc. Starts Global Phase 3 Clinical Trials Of Collategene® For Critical Limb Ischemia 10/6/2014
AcelRx Pharmaceuticals (ACRX) Release: Sufentanil Sublingual Tablet System Study Results To Be Presented At The International Association For The Study Of Pain Meeting 10/6/2014
Icon Bioscience Reports Last Patient Out In Its Phase 3 Study Of IBI-10090 As A Dropless, Sustained-Released Therapeutic For Inflammation Associated With Cataract Surgery 10/6/2014
Peregrine Pharmaceuticals, Inc. (PPHM) Release: Data To Be Presented At CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance The Anti-Tumor Activity Of Immune Checkpoint Inhibitors By Decreasing Levels Of Myeloid Derived Suppressor Cells (MDSC) In The Tumor Microenvironment 10/6/2014
FDA Grants Durata Therapeutics, Inc.  (DRTX) A Special Protocol Agreement (SPA) For Its Phase 3 Study Of DALVANCE(TM) In Hospitalized Community-Acquired Pneumonia 10/3/2014
Neurocrine Biosciences, Inc. (NBIX) Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study 10/3/2014
CEL-SCI (CVM) Enrolls 16 Patients In September In Its Phase 3 Immunotherapy Head And Neck Cancer Trial 10/3/2014
Norgine Enrolls First Patient In The Phase 3 NOCT Study To Evaluate Bowel Cleansing Efficacy Of NER1006, A Novel, Low Volume Bowel Preparation, Vs. Trisulfate 10/3/2014
Boston's Intarcia Therapeutics, Inc. Touts Trial Results Of Potentially Revolutionary Type 2 Diabetes Treatment 10/2/2014
ReVance Therapeutics, Inc. (RVNC) Provides Update On RT001 Clinical Program For The Lead Indication For Crow's Feet Lines 10/2/2014
Amgen (AMGN) Release: The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol 10/2/2014
Novartis AG (NVS) To Roll Out 15 Abstracts At EADV 10/1/2014
Portola Pharmaceuticals, Inc.'s ANNEXA™ Reverses Effect Of Anti-Clotting Drugs In Phase 3 Study 10/1/2014
XOMA (US) LLC (XOMA) Initiates U.S. Clinical Trial Of Gevokizumab In Patients With Behcet's Disease Uveitis - EYEGUARD™-U.S. 10/1/2014
Zafgen (ZFGN) Announces Initiation Of Phase 3 Trial Of Beloranib In Prader-Willi Syndrome 10/1/2014
ERYtech Pharma Reports Positive Top-Line Phase III Results From Clinical Study With GRASPA® In Acute Lymphoblastic Leukemia 10/1/2014
Shionogi, Inc. Announces Four Abstracts To Be Presented At The 25th Annual Meeting Of The North American Menopause Society (NAMS) In Washington, DC 10/1/2014
Alnylam Pharmaceuticals (ALNY) Initiates EXPLORE, A Prospective Observational Study Of Patients With Hepatic Porphyrias 10/1/2014
Salix Pharmaceuticals, Ltd. (SLXP) Release: FDA Approves RELISTOR® Subcutaneous Injection For The Treatment Of Opioid-Induced Constipation In Patients With Chronic Non-cancer Pain 9/30/2014
TherapeuticsMD, Inc.  (TXMD) Begins Phase 3 Clinical Trial Of TX-004HR (VagiCapTM) For The Treatment Of Painful Intercourse, A Symptom Of VVA, Due To Menopause 9/30/2014
Genentech (RHHBY)’s Investigational Combination Of Cobimetinib Plus Zelboraf (Vemurafenib) Provided Significant Benefit To People With Advanced Melanoma Over Zelboraf Alone 9/29/2014
Seattle Genetics, Inc. (SGEN) To Host Conference Call And Webcast On September 29, 2014 Regarding Top-Line Data From ADCETRIS® (brentuximab vedotin) Phase 3 AETHERA Clinical Trial 9/29/2014
Seattle Genetics, Inc. (SGEN) And Takeda Pharmaceutical Co. Ltd. (TKPYY) Announce Positive Data From Phase 3 AETHERA Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) For Consolidation In Post-Transplant Hodgkin Lymphoma 9/29/2014
Novartis AG (NVS) Drug Afinitor Is First Treatment For Advanced Pancreatic NET To Provide Overall Survival Of More Than 3.5 Years In Phase 3 Trial 9/29/2014
Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) 9/29/2014
Janssen Research & Development Release: ZYTIGA® Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis In Chemotherapy-Naive Men With Metastatic Castration-Resistant Prostate Cancer 9/29/2014
Keryx Biopharmaceuticals (KERX) Initiates Pivotal Phase 3 Study Of Ferric Citrate For The Treatment Of Iron Deficiency Anemia In Patients With Non-Dialysis Dependent Chronic Kidney Disease 9/29/2014
Agile Therapeutics, Inc. Announces Dosing Of First Patients In Twirla® Phase 3 SECURE Study 9/29/2014
Janssen Pharmaceutical Inc. Release: ZYTIGA®* Plus Prednisone Demonstrates Statistically Significant Overall Survival In Men With Advanced Prostate Cancer Prior To Chemotherapy 9/29/2014
Boehringer Ingelheim Corporation's Afatinib Meets Primary Endpoint In Phase 3 Study Of Head And Neck Cancer 9/29/2014
SALVAT Announces Positive Top-Line Results From Two Phase 3 Studies Of Its Novel Otic Antibiotic/Steroid Combination Solution In The Treatment Of AOMT With Tympanostomy Tubes 9/29/2014
Exelixis, Inc. (EXEL) Announces Positive Results From Phase 3 Pivotal Trial Of Cobimetinib In Combination With Vemurafenib In Patients With BRAF V600 Mutation-Positive Advanced Melanoma 9/29/2014
Roche (RHHBY)’s Perjeta Regimen Extended The Lives Of People With An Aggressive Type Of Metastatic Breast Cancer By 15.7 Months Compared To Herceptin And Chemotherapy 9/29/2014
Helsinn Group Release: Pivotal Phase 3 Trial Data For Anamorelin In ROMANA 1 And 2 Studies In Non-Small Cell Lung Cancer Patients With Anorexia-Cachexia Shows Significant Increase In Lean Body Mass, Body Weight And Improved Symptoms 9/29/2014
Roche (RHHBY)’s Investigational Combination Of Cobimetinib Plus Zelboraf® (Vemurafenib) Provided Significant Benefit To People With Advanced Melanoma Over Zelboraf Alone 9/29/2014
Provectus Biopharmaceuticals Inc. Data Presented At ESMO 2014 Congress Show Ablative, Bystander Effects Of PV-10 9/29/2014
Bristol-Myers Squibb Company (BMY) Positive Phase 3 Data For Opdivo (Nivolumab) In Advanced Melanoma Patients Previously Treated With Yervoy (Ipilimumab) Presented At The ESMO 2014 Congress; First Phase 3 Results Presented For A PD-1 Immune Checkpoint Inhibitor 9/29/2014
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Cancer Drug Meets Main Goal In Phase 3 Trial 9/29/2014
Pfizer (PFE) Delays Start Of Phase 3 Rivipansel Trial, GlycoMimetics, Inc. (GLYC) Shares Fall 9/26/2014
Novartis AG (NVS) Reports Two Positive Phase 3 Trials For Arthritis Drug 9/26/2014
Immunomedics, Inc. (IMMU) Publishes Results On Immunotherapy Of Solid Cancers Mediated By A Novel Bispecific Antibody 9/26/2014
Cempra Pharmaceuticals, Inc. Completes Enrollment Of Solitaire-Oral Phase 3 Trial 9/26/2014
Bausch & Lomb Announces Successful Results From Phase 3 Study Of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38% 9/26/2014
Navidea Biopharmaceuticals (NAVB)’s Lymphoseek® Recommended By CHMP For European Approval In Sentinel Lymph Node Detection For Melanoma, Breast And Certain Head And Neck Cancers 9/26/2014
Nektar Therapeutics (CA) (NKTR) Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation 9/26/2014
Roche (RHHBY)’s Avastin Prolongs Life In Breast Cancer Study 9/25/2014
NicOx SA (COX.PA) Gets Boost From Strong Prospects For Glaucoma Drug Vesneo 9/25/2014
Gilead Sciences, Inc. (GILD)'s Single Tablet HIV Regimen Meets Goals In Two Phase 3 Studies 9/25/2014
Helsinn Announces That Pivotal Phase 3 Trial Data For Anamorelin In ROMANA 1 And 2 Studies In Non-Small Cell Lung Cancer Patients With Anorexia-Cachexia Will Be Presented At The 38th European Society For Medical Oncology (ESMO) Congress In 2014 9/25/2014
Radiant Research/Clinical Research Advantage, Inc. Enrolls More Than 8,000 Subjects For Hepatitis B Vaccine Study 9/25/2014



//-->